Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-07-23

Clinical Trial Update: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating retatrutide (LY3437943) for obesity with cardiovascular disease is active but not currently recruiting, under Eli Lilly and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Retatrutide (retatrutide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity, Cardiovascular Diseases | Phase 3 | Status: ACTIVE_NOT_RECRUITING